Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, leading with tecarfarin, a new Vitamin K ...

Anticoagulant rodenticides (ARs ... these substances pose significant risks to non-target wildlife, including predators and scavengers that may consume poisoned rodents. Recent research has ...

“Studies have shown that healthcare utilization at the end of life is high, and patients receive aggressive medical care that ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), a biopharmaceutical company specializing in cardiovascular therapies with a market capitalization of $35.2 million and impressive 210% ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's <a target=_blank ...

I was about ten years old when a horse fly bit me. I was on a camping trip. I saw the giant fly land on my leg. It went to ...

Factor XI has emerged as a target for anticoagulants that have the potential to be safer than currently available agents because there is mounting evidence that factor XI is essential for ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...

We aimed to assess and quantify current time metrics in anticoagulant-associated ICH (AAICH ... Mean admission systolic BP was 177.2±28.6 mmHg, with a 140 mmHg BP target in 94%. At 60 minutes from ...